Clinical Trial Update: Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase I/Phase II dose-escalation trial evaluating topotecan with pazopanib in children with recurrent or refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors in Children

Drugs mentioned

• Pazopanib (Pazopanib)
• Topotecan (topotecan)

Snippet

Sponsor: The Hospital for Sick Children | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED